Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic ALK+ Non Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT02228421
What this trial is testing

Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
PeriPharm 29
Testing effectiveness (Phase 2)Ended earlyNCT03666728
What this trial is testing

SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Who this might be right for
Lung Neoplasms
Jiangsu HengRui Medicine Co., Ltd. 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06951399
What this trial is testing

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IV Without EGFR/ALK MutationNSCLC Adenocarcinoma
Rabin Medical Center 30
Not applicableStudy completedNCT03546894
What this trial is testing

Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Who this might be right for
Anaplastic Lymphoma Kinase-positiveCarcinoma Non-small-cell Lung
Takeda 111
Not applicableStudy completedNCT05167500
What this trial is testing

Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Fundación GECP 118
Testing effectiveness (Phase 2)Study completedNCT01685138
What this trial is testing

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 124
Early research (Phase 1)Study completedNCT02299505
What this trial is testing

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 306
Testing effectiveness (Phase 2)Study completedNCT03647488
What this trial is testing

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT03808662
What this trial is testing

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Who this might be right for
TNBC - Triple-Negative Breast CancerTriple Negative Breast CancerNSCLC+4 more
Memorial Sloan Kettering Cancer Center 107
Testing effectiveness (Phase 2)Study completedNCT03779191
What this trial is testing

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Who this might be right for
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Instituto Nacional de Cancerologia de Mexico 41
Large-scale testing (Phase 3)Active Not RecruitingNCT06082635
What this trial is testing

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Shenzhen TargetRx Co., Ltd. 321
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Early research (Phase 1)Study completedNCT02959619
What this trial is testing

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Who this might be right for
Solid TumorNon-Small Cell Lung Cancer Metastatic
Betta Pharmaceuticals Co., Ltd. 48
Not applicableUnknownNCT04317651
What this trial is testing

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerAdvanced CancerMetastatic Cancer
Fondazione Ricerca Traslazionale 500
Large-scale testing (Phase 3)Study completedNCT01828112
What this trial is testing

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 231
Testing effectiveness (Phase 2)Study completedNCT02314364
What this trial is testing

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticTargetable Oncogenes (EGFR, ALK, ROS1)
Massachusetts General Hospital 27
Early research (Phase 1)Looking for participantsNCT07140016
What this trial is testing

Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc. 40
Not applicableUnknownNCT02041468
What this trial is testing

Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Jewish General Hospital 29
Not applicableActive Not RecruitingNCT05721950
What this trial is testing

Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 154
Not applicableUnknownNCT06410040
What this trial is testing

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Who this might be right for
ALK-positive Non-small Cell Lung CancerBrain MetastasesMeningeal Metastasis
Sichuan Cancer Hospital and Research Institute 28
Next Page